Adjustable height needle infusion device

Abstract
An infusion set has a retraction dial that can be removably assembled with the infusion set and access a threaded needle hub contained therein such that the dial can be used to advance or retract a needle hub and an inserted needle to a more precisely controlled insertion depth to deliver insulin or other medicament intradermally (i.e. to the upper 3 mm of skin surface). Position of the inserted needle can be maintained by providing a separated and isolated needle hub, main base and main hub of the infusion set that can isolate the inserted needle from external forces such that the needle can be maintained at a depth to deliver content to the upper 3 mm of skin surface during normal use.
Description
FIELD OF THE INVENTION

The present invention relates generally to components and elements of infusion sets, including a retraction dial for an infusion set, which ensures proper positioning of needle insertion by removably coupling with an infusion set and allowing a user to adjust a final needle depth by turning the dial.


BACKGROUND OF THE INVENTION

A large number of people, including those suffering from conditions such as diabetes use some form of infusion therapy, such as daily insulin infusions to maintain close control of their glucose levels. There are two principal modes of daily insulin therapy. The first mode includes syringes and insulin pens. These devices are simple to use and are relatively low in cost, but they require a needle stick at each injection, typically three to four times per day. The second mode includes infusion pump therapy, which entails the purchase of an insulin pump that lasts for about three years. The initial cost of the pump can be significant, but from a user perspective, the overwhelming majority of patients who have used pumps prefer to remain with pumps for the rest of their lives. This is because infusion pumps, although more complex than syringes and pens, offer the advantages of continuous infusion of insulin, precision dosing and programmable delivery schedules. This results in closer blood glucose control and an improved feeling of wellness.


The use of an infusion pump requires the use of a disposable component, typically referred to as an infusion set or pump set, which conveys the insulin from a reservoir within the pump into the skin of the user. An infusion set typically consists of a pump connector, a length of tubing, and a hub or base from which an infusion needle or cannula extends. The hub or base has an adhesive which retains the base on the skin surface during use, and may be applied to the skin manually or with the aid of a manual or automatic insertion device.


Currently, most insulin infusion sets deliver insulin to the sub-cutaneous layers of skin using either fixed metal needles or flexible plastic cannulas. Such infusion sets typically deliver insulin 4-10 mm below the skin surface. However, the upper 3 mm of skin surface, the intradermal space, facilitates better drug absorption. Unfortunately, due to the relative thinness of the intradermal layer, inserting a needle at such depth and maintaining an infusion site over an extended period of time within this narrow band is difficult.


Further, most insulin infusion sets typically do not provide any features to isolate the inserted needle from shock or other external forces. Since these infusion sets typically deliver insulin 4-10 mm below the skin surface, shock or other external forces to the set have less effect on the deeper inserted needle. However, where an attempt is made to target the upper 3 mm of skin surface, any shock or movement of the set can adversely affect needle insertion and infusion performance.


Still further, most insulin sets have inserters that can result in skin surface “tenting” during needle insertion, where the skin surface is deflected somewhat prior to or during needle insertion, which makes precisely targeting the upper 3 mm of skin surface difficult.


Accordingly, a need exists for advanced, improved, and novel components and elements of current and future infusion sets that can deliver content to the upper 3 mm of skin surface, the intradermal space, to facilitate better drug absorption, while maintaining a degree of comfort to the user.


SUMMARY OF THE INVENTION

An object of the present invention is to provide an infusion set which can deliver insulin or other medicament to the upper 3 mm of skin surface, the intradermal space, to facilitate better drug absorption, while maintaining a degree of comfort to the user.


Another object of the present invention is to provide an infusion set having an inserter that can insert a needle which can be removed from the infusion set after insertion.


Another object of the present invention is to provide an infusion set with a removable retraction dial on its upper surface, wherein the retraction dial can be used to precisely retract an inserted needle to reach a desired depth to deliver insulin or other medicament to the upper 3 mm of skin surface, or retract an inserter needle some distance into a soft cannula after insertion.


Another object of the present invention is to provide an infusion set that includes a needle hub in a threaded engagement with a main base, such that rotation of the needle hub relative to the main base results in retraction or advancement of a needle of the needle hub.


Another object of the present invention is to provide an infusion set with the removable retraction dial to rotate the needle hub relative to the main base to precisely retract an inserted needle to reach a desired depth to deliver insulin or other medicament to the upper 3 mm of skin surface.


Another object of the present invention is to provide an infusion set that can isolate an inserted needle from external forces such that the needle can be maintained at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface during normal use.


These and other objects are substantially achieved by providing an infusion set having a retraction dial that can be removably assembled with the infusion set and access a threaded needle hub contained therein such that the dial can be used to advance or retract an inserted needle to a depth to deliver insulin or other medicament to the upper 3 mm of skin surface, or retract an inserter needle some distance into a soft cannula after insertion. Position of the inserted needle can be maintained by providing a needle hub, main base and main hub of the infusion set that can isolate the inserted needle from external forces such that the needle can be maintained at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface during normal use.





BRIEF DESCRIPTION OF THE DRAWINGS

The various objects, advantages and novel features of the exemplary embodiments of the present invention will be more readily appreciated from the following detailed description when read in conjunction with the appended drawings, in which:



FIG. 1 is a perspective view of an infusion set in accordance with an embodiment of the present invention;



FIG. 2 is a bottom perspective view of the infusion set of FIG. 1;



FIG. 3 is a cross-sectional view of the infusion set of FIG. 1 showing the needle in an inserted position, but prior to user retraction, in accordance with an embodiment of the present invention;



FIG. 4 is a bottom perspective view of the infusion set of FIG. 1 shown without an adhesive layer for illustrative purposes in accordance with an embodiment of the present invention;



FIG. 5 is a top perspective view of the infusion set of FIG. 1 with the retraction dial removed in accordance with an embodiment of the present invention;



FIG. 6 is a bottom perspective view of the infusion set of FIG. 1 illustrating a soft cannula insertion in accordance with an embodiment of the present invention; and



FIG. 7 is a top perspective view of the infusion set of FIG. 1 with the retraction dial removed and the infusion pump tube connection in place in accordance with an embodiment of the present invention.





Throughout the drawings, like reference numerals will be understood to refer to like parts, components and structures.


DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS

The exemplary embodiments of the present invention described below provide a novel means of delivering insulin to the intradermal layers of skin via a standard insulin pump. In particular, the exemplary embodiments of the present invention provide an infusion set with a retraction dial to advance or retract an inserted needle to deliver insulin to the upper 3 mm of skin surface, the intradermal space, to facilitate better drug absorption, while maintaining a degree of comfort to the user.


As will be appreciated by one skilled in the art, there are numerous ways of carrying out the examples, improvements and arrangements of insulin-associated devices disclosed herein. Although reference will be made to the exemplary embodiments depicted in the drawings and the following description, the embodiments disclosed herein are not meant to be exhaustive of the various alternative designs and embodiments that are encompassed by the disclosed invention.


As noted, the exemplary embodiments of the present invention deliver insulin to the intradermal layers of the skin via a standard insulin pump or other similar device. By utilizing a retraction dial, and an isolated needle hub, proper insertion and maintenance of the inserted needle in the intradermal space is ensured. Position of the inserted needle can be maintained by providing a needle hub, main base and main hub of the infusion set, and tube attachment, that can isolate the inserted needle from external forces such that the desired needle depth can be maintained.


Proper needle insertion stands as a primary obstacle to infusing insulin via a pump into the intradermal layer. In the exemplary embodiments of the present invention, the initial insertion of the needle is substantially the same as performed using any standard infusion set, but a removable retraction dial is provided to advance or retract the inserted needle, or retract an inserter needle some distance into a soft cannula after insertion. By retracting the inserted needle a slight distance, medicament can be delivered into the thin intradermal layer. Utilizing precision parts, this process can be reliable when compared to a standard manual intradermal injection procedure, such as the Mantoux technique.


However, maintaining the position of the needle within the intradermal layers of the skin over the course of a typical three-day period poses significant technical challenges. Accordingly, the exemplary embodiments of the present invention further provide at least two methods of anchoring the needle in place. First, the main base of the device creates and maintains a preload on the skin surface, which locks the needle in place vertically. Second, an adhesive may be applied to the main base in the area of the needle, locking the skin surface to the needle location.



FIGS. 1 and 2 are perspective views of an infusion set in accordance with an embodiment of the present invention. As shown in FIGS. 1-3, the exemplary infusion set 10 can comprise an outer hub 12, main hub 14, main base 16, needle hub 18, and retraction dial 20. An outer ring 22 rotatably extends between the outer hub 12 and retraction dial 20. The hub, base and other elements can be constructed of a molded plastic material, polycarbonate, thermoplastic polymer such as polyethylene terephthalate (PET and PETG), or similar materials.


As shown in greater detail in FIGS. 2 and 3, the needle hub 18 is positioned within the main base 16, and comprises a needle 24. The main base 16 contains the needle hub 18 and an optional needle hub adhesive layer 26. A main base inner adhesive layer 28 can also be provided on the main base 16, and an outer hub adhesive layer 30 can be provided on the outer hub 12.


The needle hub 18 is held within an opening of the main base 16 via a helical threaded engagement between the needle hub 18 and the main base 16. A female thread groove 17 in the wall of opening 38 receives a male thread 19 on the needle hub 18. In doing so, rotation of the needle hub 18 within the opening 38 of the main base 16 serves to advance or retract the needle hub 18 via the threaded engagement, within the opening 38 of the main base 16, thereby advancing or retracting the needle 24 relative to the main base 16 adhered to the skin surface.


The main hub 14 rotatably covers the main base 16 and provides a fluid communication channel 52 between an inner septum 32 and a valve connection septum 34. The main hub 14 is held in place by the flexible tube connection 48 between the main hub 14 and the outer ring 22, as shown in FIG. 4, and by the geometry of the main base 16 and the outer ring 22. As illustrated in FIG. 3, the needle 24 comprises first and second ends, wherein the first end is configured to penetrate a skin surface (not shown), and the second end (which may be sharpened or unsharpened) is configured to penetrate an inner septum 32 (which may be pre-slit and/or pierceable) as described in greater detail below. The inner septum 32 is held within a protrusion 36 of the main hub 14, which is configured to slidably engage a similarly shaped opening 54 in the needle hub 18 as the needle hub is advanced or retracted. The needle 24 can comprise a 31 gauge, 3 mm in length, single-bevel stainless steel needle/cannula, but is not limited thereto. In other embodiments of the present invention, the needle 24 can be plastic or other material, between 27 gauge and 34 gauge, between 2 mm and 5 mm in length, and be provided with a tri-bevel or 5-bevel needle. The needle 24 can be bonded to the needle hub 18 with an adhesive, such as a Loctite/UV cured adhesive, or can be over molded with, or threaded into, the needle hub. Further, other embodiments of the present invention, the needle 24 can be replaced with a soft cannula provided with an internal introducer needle that can be retracted inside the soft cannula. The needle 24 can also comprise a needle longer than that used to simply target the intradermal layer, since the needle of the exemplary embodiments of the present invention is first inserted to a depth of, for example, 5 mm to 6 mm, and then retracted to the targeted intradermal depth of, for example, 3 mm or less. As described in greater detail below, this allows use of a longer needle, minimizes the risk of tenting or skin deflection affecting the final insertion depth, and creates an opening to minimize pressure.


The example shown in FIG. 3 illustrates an infusion set wherein the needle 24 has been inserted (or, in the case of a soft cannula and internal introducer needle, wherein the soft cannula and introducer needle have been inserted), and the retraction dial 20 exposed. The retraction dial 20 comprises at least one member 40 extending through an opening 56 of the main hub 14 and terminating in an opening 58 of the needle hub 18 to transmit a rotary force thereto.


The retraction dial 20 is configured to cover the main hub 14 and main base 16 to permit user adjustment of the needle 24 depth. To do so, the retraction dial 20 comprises the least one member 40 extending through the opening 56 of the main hub 14 and terminating in the opening 58 of the needle hub 18. Accordingly, when the retraction dial 20 and member 40 are turned, the main hub 14 and needle hub 18 are turned with the retraction dial 20. However, the main base 16 remains stationary, in adhesive contact with the skin surface. Accordingly, as the needle hub 18 is rotated by the member 40, the threaded engagement with the stationary main base 16 results in an upward or downward movement of the needle hub 18 and the attached needle 24 (or, in the case of a soft cannula and internal introducer needle, results in the introducer needle being retracted or advanced inside the soft cannula).


Accordingly, by turning the retraction dial 20, a user can retract (i.e., move upward) the needle 24. In doing so, a desired depth of needle penetration can be achieved more precisely. Further, the passageway initially created by the fully inserted needle, results in an opening or unfilled passageway as the needle 24 is slightly retracted. The benefits associated with infusion to this additional unfilled passageway are described below. Still further, as the needle 24 is retracted, the second end of the needle 24 contacts and pierces the inner septum 32, such that the needle 24 is in fluid communication with the channel 52 of the main hub 14.


The retraction dial 20 is further configured to simply pull free from the main hub 14 and main base 16 after the desired retraction, as the member 40 is simply held in place by friction engagement with the through-openings 56 and 58, and the opening 60 between the main hub 14 and outer ring 22. Accordingly, upon reaching the desired retraction depth, which can be denoted by a positive stop or some other user-detectable feature, the retraction dial 20 can be removed, thereby leaving the device as shown in FIG. 5. The retraction dial 20 can be marked to denote needle depth, or can be configured to release from the infusion set when the needle reaches a desired depth (i.e. about one rotation or 360 degrees). Still further, it may be desirable to retain the retraction dial 20 in place for later needle height adjustments. By allowing the user to make minute adjustments to the needle height within the intradermal layer, tissue tolerance of infusion may increase. Also, occlusions caused by foreign body response at the end of the needle may be released by these movements. Such a height adjustment feature is easy to adjust in small increments, yet difficult to move accidentally. A release button (not shown) can also be provided. It can also be possible to allow the user to selectively adjust the height to either a subcutaneous or intradermal height setting.


In yet another exemplary embodiment of the present invention shown in FIG. 6, an internal introducer needle 124 can be used to insert a soft cannula 126, and then be partially retracted or withdrawn a distance into the cannula using the retraction dial 20. In this case, the retraction dial 20 can be used to control a distance the introducer needle is withdrawn into the cannula, and subsequently, to control the length of flexible cannula free of the introducer needle. For example, the device can be used to insert the soft cannula 126 and the retraction dial 20 can be used to retract or withdraw the introducer needle 124 some distance back into the soft cannula. The soft cannula can comprise Teflon or Vialon, and be between 25 gauge and 32 gauge. In such an exemplary embodiment, a steel introducer needle can be provided and be between 27 gauge and 34 gauge for proper fitting inside the soft cannula.


At this time, the infusion pump tube attachment 42 and tubing 44 to the infusion pump (not shown) can be attached to the top of the infusion set as shown in FIG. 7. FIG. 7 is a top perspective view of the infusion set of FIG. 1 with the retraction dial removed and the infusion pump tube connection in place. The infusion pump tube attachment 42 comprises a circular cover piece to which the tubing 44 is attached and routed through to a septum piercing member (not shown) to engage and pierce the valve connection septum 34. Alignment between the infusion pump tube attachment 42 and the valve connection septum 34 is achieved through the engagement with the self-alignment features, or slots, 46 in the outer ring 22. For example, an inner surface of the cover piece of the infusion pump tube attachment 42 can comprise one or more projections or boss features (not shown) which mate with the slots 46 to thereby allow complete downward assembly of the infusion pump tube attachment 42 with the infusion set when the valve connection septum 34 is in alignment for piercing.


In addition, the infusion pump tube attachment 42 is free to rotate 360 degrees, allowing the tubing 44 to the pump to be arranged in a comfortable orientation. To do so, the outer ring 22 to which the tube attachment 42 is secured, is rotatable between the outer hub 12 and the main hub 14. Specifically, the outer ring 22 of the device is configured to be rotatable along track-like features 62 in the outer hub 12, which is fixed to the user's skin surface. By connecting the outer hub 12 and the outer ring 22 via the track features 62, and connecting the outer ring 22 to the main hub 14 via the thin flexible length of tubing 48, the outer ring 22 and valve connection septum 34 can rotate as permitted by the flexible tubing 48. In doing so, the infusion pump tube attachment 42 is permitted to rotate. In the exemplary embodiment shown, the flexible tubing 48 at least partially encircles the main hub 14 and main base 16, which permits a shorter or flatter device profile.


Vibrational and shock isolation of the main hub 14 and main base 16, from the outer hub 12, outer ring 22 and valve connection septum 34, is achieved in a number of ways, including the provision of the track features 62 between the outer hub 12 and the outer ring 22, and the flexible tubing 48 between the fluid channel 52 of the main hub 14 and connection valve 50 of the outer ring 22. Further, once the retraction dial 20 is removed, the main hub 14 and main base 16 are separated from the outer hub 12 and outer ring 22. That is, first, the main hub 14 and the outer ring 22 are physically separated and are connected only by the flexible tubing 48, and second, the main hub 14 and main base 16 are secured to the skin surface via adhesive layers 26 and 28, and the outer hub 12 is secured to the skin surface via adhesive layer 30, wherein the layers 26, 28 and 30 are physically separated. In doing so, the only connection between the main hub 14 and main base 16, and the outer hub 12 and outer ring 22 (and the attached infusion pump tube attachment 42), is the flexible tubing 48. Further, once covered by the tube attachment described in greater detail below, external contact with the main hub 14 and main base 16 is prevented.


The exemplary embodiments of the present invention provide a novel means of delivering insulin to the intradermal layers of skin via standard insulin pumps, but are not limited thereto. The invention can also be applied to patch pumps or other infusion devices.


Further, the exemplary embodiments comprise a straight microneedle, needle, or other cannula, that can be inserted by the user into the deeper dermis or the subcutaneous layers of the skin, and can then be withdrawn with a great deal of precision into the dermal layer, where it is held by adhesive and/or mechanical preload.


Initial insertion of the infusion set with a user controllable needle depth is similar to the operation of fixed steel cannula devices currently on the market. The user first peels off a flexible backing, removes a needle cover, and then inserts the needle into the infusion site. After ensuring good skin adhesion, the user then turns the retraction dial. The retraction dial can be marked to denote needle depth, reach a positive stop, or can be configured to release from the infusion set when the needle reaches a desired depth (i.e. about one rotation or 360 degrees). In an exemplary embodiment, the retraction dial is configured to turn a quarter turn (i.e., 90 degrees) to reach the desired depth. The user can then remove the retraction dial and attach the pump tube attachment, in the case of an infusion set, from the top of the device. The device is then ready to prime and deliver insulin. In addition, the valve connection is free to rotate up to 360 degrees, allowing the tubing to the pump to be arranged in a comfortable orientation.


As the retraction dial 20 turns, the needle 24 and needle hub 18 of the device move up the threaded engagement 17 and 19 located in the main base 16. The needle 24 protrudes from both sides of the needle hub 18 and, on the side opposite the side that pierces the skin, the needle 24 pierces through the inner septum 32 as it moves upward, establishing fluid communication with the valve connection interface. As the needle 24 pierces the inner septum 32 in such a manner, it can be locked in place with respect to the main base 16. To do so, a detent or projection (not shown) can be provided on an outer surface of the needle hub 18 that is configured to mate with a similar detent or projection (not shown) provided on an inner surface of the main base 16 when the needle hub 18 reaches the desired position. Once engaged, the detents can lock the needle hub 18 in place with the main base 16. The fluid path 30 is open through the main hub 14 and the flexible piece of tubing 48 which leads to the valve connection septum 34 located in the outer ring 22, which is able to rotate about the main hub 14 and main base 16 as permitted by the track in the outer hub 12 and tubing 48.


As shown in FIG. 3, the main base 16 also provides a contour on a lower surface that contacts the skin surface around the needle 24, providing a slight preload, or indentation, on the skin surface which helps maintain the needle position within the intradermal layer. In addition, adhesive layer 26 can be placed on the main base 16 in the vicinity of the needle 24 to help with the anchoring of the needle in the skin surface.


The outer ring 22 of the device is configured to be rotatable along the track-like features 62 in the outer hub 12, which is fixed to the user's skin surface. By connecting the outer hub 12 and the outer ring 22, to the main hub 14 and main base 16, via the thin flexible length of tubing 48, external forces and vibrations are absorbed by the outer hub 12 and the outer ring 22, but not by the main hub 14, main base 16, needle hub 18 and the needle 24. Finally, the infusion pump tube attachment 42 can be attached to the outer ring 22, covering the assembly and providing further isolation of the needle, and the self-centering features of slots 46 ensure that the valve connection needle (not shown) pierces the valve connection septum 34.


As noted above, the passageway initially created by the fully inserted needle, results in an opening or unfilled passageway as the needle 24 is slightly retracted. As known in the art, high pumping pressure (i.e., 20-50 or more psi), can occur during intradermal infusion. However, by first providing the deeper insertion tunnel established by the initial insertion depth as recited above, and the subsequent withdrawal to the intradermal layer, embodiments of the present invention can relieve such pressures by increasing the surface area of the deposition area.


Further, by infusing into the intradermal layer of the skin, the exemplary embodiments of the present invention offer the potential for better absorption of insulin when compared to subcutaneous delivery systems. In doing so, it may be possible for the typical user to both consume less insulin and maintain a better medicament regime.


Other intradermal infusion set concepts are at risk of “tenting”, which is the undesired effect where skin is deflected at needle insertion before or during insertion, creating a shape similar to a tent. In doing so, the skin surface tents during needle insertion rather than needle penetration into the skin. However, since a longer needle can be used, and then slightly retracted in the exemplary embodiments of the present invention, the risk of tenting or skin deflection otherwise affecting final insertion depth is reduced. Still further, a small intradermal needle placed perpendicular to the skin and isolated from outside forces causes less pain to the user during use.


In current steel cannula infusion sets which deliver to the subcutaneous layer, the needle is not isolated from any undesired outside forces which may cause pain when translated to the needle and the needle moves within the skin. Also, other intradermal devices face problems of premature or otherwise undesired needle removal when the device is bumped, if the needle is not isolated from the outside forces.


In the exemplary embodiments of the present invention, the intradermal needle is isolated from outside forces by a cover design, a double ring feature, and the provision of flexible tubing. Such features help to effectively isolate the needle from the outside forces and other interferences.


By infusing into the intradermal layer of the skin, the exemplary embodiments of the present invention offer the potential for better absorption of the insulin when compared to subcutaneous delivery systems. It may be possible for the user to maintain a better medicament regimen while using less insulin. Further, the provision of a small intradermal needle placed perpendicular to the skin and isolated from outside forces causes less pain and discomfort to the user during use.


Although only a few exemplary embodiments of the present invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the appended claims and their equivalents.

Claims
  • 1. An infusion set, comprising: a main base, comprising a moveable needle hub; anda rotation element, comprising a user-rotatable top surface of said infusion set and releasably coupled with said moveable needle hub within said main base, wherein said rotation element is configured to rotate relative to said main base and wherein said rotation is translated into vertical movement of said moveable needle hub within said main base.
  • 2. An infusion set as claimed in claim 1, further comprising a threaded engagement between said moveable needle hub and said main base.
  • 3. An infusion set as claimed in claim 1, further comprising: a main hub, disposed on said main base, said main hub comprising a fluid channel and an inner septum at a first end of said channel, and a flexible tube at a second end of said channel;an outer hub, separated from said main hub; andan outer ring, rotatably captured by said outer hub and surrounding said main hub, wherein said main hub is coupled to said outer ring via said flexible tube, and wherein said main hub and said main base are separated from said outer ring and said outer hub.
  • 4. An infusion set as claimed in claim 3, further comprising: a first adhesive layer disposed on said main base; anda second adhesive layer disposed on said outer hub, wherein said first adhesive layer is separated from said second adhesive layer.
  • 5. An infusion set as claimed in claim 3, further comprising at least one of: a needle secured by said needle hub and having a first end configured to contact a skin surface, and a second end configured to pierce said inner septum, wherein said needle is configured to be inserted to a first depth and retracted to a second depth by said vertical movement of said moveable needle hub within said main base; anda soft cannula and internal introducer needle secured by said needle hub and having a first end configured to contact a skin surface, and a second end configured to pierce said inner septum, wherein said internal introducer needle is configured to be inserted to a first depth and retracted to a second depth within said soft cannula by said vertical movement of said moveable needle hub within said main base.
  • 6. An infusion set as claimed in claim 3, wherein said outer ring comprises a connection valve coupled with said flexible tubing, and a connection valve septum configured to pierceably receive a tube attachment cover.
  • 7. An infusion set as claimed in claim 3, further comprising a tube attachment cover, configured to releasably couple with said outer ring and cover said main hub, without contacting said main hub.
  • 8. An infusion set as claimed in claim 1, wherein said main base comprises a contoured skin contact surface.
  • 9. An infusion set as claimed in claim 1, wherein said main base comprises a third adhesive layer disposed about a needle opening in said main base.
  • 10. An infusion set as claimed in claim 1, wherein said set can be constructed of at least one of a molded plastic material, polycarbonate, thermoplastic polymer such as polyethylene (PET and PETG), or similar material.
  • 11. An infusion set as claimed in claim 1, wherein said rotation element comprises a dial, releasably coupled with said moveable needle hub within said main base.
  • 12. A depth-targeting infusion system, comprising: an infusion set; anda rotation element, comprising a user-rotatable top surface of said infusion set and releasably coupled with said infusion set, wherein said rotation element is configured to rotate relative to said infusion set and wherein said rotation is translated into vertical movement of a moveable needle hub within said infusion set.
  • 13. An infusion system as claimed in claim 12, wherein said infusion set comprises: a main base, comprising a moveable needle hub;a main hub, disposed on said main base, said main hub comprising a fluid channel and an inner septum at a first end of said channel, and a flexible tube at a second end of said channel;an outer hub, separated from said main hub; andan outer ring, rotatably captured by said outer hub and surrounding said main hub, wherein said main hub is coupled to said outer ring via said flexible tube, and wherein said main hub and said main base are separated from said outer ring and said outer hub.
  • 14. An infusion system as claimed in claim 13, further comprising a threaded engagement between said moveable needle hub and said main base.
  • 15. An infusion system as claimed in claim 13, further comprising: a first adhesive layer disposed on said main base; anda second adhesive layer disposed on said outer hub, wherein said first adhesive layer is separated from said second adhesive layer.
  • 16. An infusion system as claimed in claim 13, further comprising at least one of: a needle secured by said needle hub and having a first end configured to contact a skin surface, and a second end configured to pierce said inner septum, wherein said needle is configured to be inserted to a first depth and retracted to a second depth by said vertical movement of said moveable needle hub within said main base; anda soft cannula and internal introducer needle secured by said needle hub and having a first end configured to contact a skin surface, and a second end configured to pierce said inner septum, wherein said internal introducer needle is configured to be inserted to a first depth and retracted to a second depth within said soft cannula by said vertical movement of said moveable needle hub within said main base.
  • 17. An infusion system as claimed in claim 13, wherein said outer ring comprises a connection valve coupled with said flexible tubing, and a connection valve septum configured to pierceably receive a tube attachment cover.
  • 18. An infusion system as claimed in claim 13, further comprising a tube attachment cover, configured to releasably couple with said outer ring and cover said main hub, without contacting said main hub.
  • 19. An infusion system as claimed in claim 13, wherein said main base comprises a contoured skin contact surface.
  • 20. An infusion system as claimed in claim 13, wherein said main base comprises a third adhesive layer disposed about a needle opening in said main base.
  • 21. An infusion system as claimed in claim 12, wherein said rotation element comprises a dial, releasably coupled with said infusion set.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §119(e) of a U.S. provisional patent application of Ryan Schoonmaker et al. entitled “Adjustable Height Needle Infusion Device”, Ser. No. 61/344,971, filed on Nov. 30, 2010, the entire content of said application being incorporated herein by reference.

US Referenced Citations (249)
Number Name Date Kind
3572336 Hershberg Mar 1971 A
3857382 Williams, Jr. et al. Dec 1974 A
3918355 Weber Nov 1975 A
3963380 Thomas, Jr. et al. Jun 1976 A
4204538 Cannon May 1980 A
4231368 Becker Nov 1980 A
4490141 Lacko et al. Dec 1984 A
4685902 Edwards et al. Aug 1987 A
4723947 Konopka Feb 1988 A
4734092 Millerd Mar 1988 A
4755173 Konopka et al. Jul 1988 A
5176662 Bartholomew et al. Jan 1993 A
5226899 Lee et al. Jul 1993 A
5242406 Gross et al. Sep 1993 A
5257980 Van Antwerp et al. Nov 1993 A
5453099 Lee et al. Sep 1995 A
5522803 Teissen-Simony Jun 1996 A
5536249 Castellano et al. Jul 1996 A
5545143 Fischell Aug 1996 A
5545152 Funderburk et al. Aug 1996 A
5593390 Castellano et al. Jan 1997 A
5728074 Castellano et al. Mar 1998 A
5800420 Gross et al. Sep 1998 A
5820602 Kovelman et al. Oct 1998 A
5851197 Marano et al. Dec 1998 A
5858001 Tsals et al. Jan 1999 A
5858005 Kriesel Jan 1999 A
5925021 Castellano et al. Jul 1999 A
5957895 Sage et al. Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5980506 Mathiasen Nov 1999 A
6017328 Fischell et al. Jan 2000 A
6056718 Funderburk et al. May 2000 A
6068615 Brown et al. May 2000 A
6074369 Sage et al. Jun 2000 A
6086575 Mejslov Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6110148 Brown et al. Aug 2000 A
6123690 Mejslov Sep 2000 A
6132400 Waldenburg Oct 2000 A
6175752 Say et al. Jan 2001 B1
6206134 Stark et al. Mar 2001 B1
6254586 Mann et al. Jul 2001 B1
6272364 Kurnik Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6277627 Hellinga Aug 2001 B1
6293925 Safabash et al. Sep 2001 B1
6302866 Marggi Oct 2001 B1
6352523 Brown et al. Mar 2002 B1
6355021 Nielsen et al. Mar 2002 B1
6391005 Lum et al. May 2002 B1
6485461 Mason et al. Nov 2002 B1
6520938 Funderburk et al. Feb 2003 B1
6521446 Hellinga Feb 2003 B2
6544212 Galley et al. Apr 2003 B2
6546269 Kurnik Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6558351 Steil et al. May 2003 B1
6565509 Say et al. May 2003 B1
6576430 Hsieh et al. Jun 2003 B1
6579267 Lynch et al. Jun 2003 B2
6589229 Connelly et al. Jul 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6613017 Mickley Sep 2003 B1
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6669669 Flaherty et al. Dec 2003 B2
6692457 Flaherty Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6706159 Moerman et al. Mar 2004 B2
6723072 Flaherty et al. Apr 2004 B2
6740059 Flaherty May 2004 B2
6749560 Konstorum et al. Jun 2004 B1
6749587 Flaherty Jun 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6830558 Flaherty et al. Dec 2004 B2
6830562 Mogensen et al. Dec 2004 B2
6840922 Nielsen et al. Jan 2005 B2
6852104 Blomquist Feb 2005 B2
6949084 Marggi et al. Sep 2005 B2
6960162 Saadat et al. Nov 2005 B2
6960192 Flaherty et al. Nov 2005 B1
6977180 Hellinga et al. Dec 2005 B2
6997907 Safabash et al. Feb 2006 B2
7004928 Aceti et al. Feb 2006 B2
7018360 Flaherty et al. Mar 2006 B2
7029455 Flaherty Apr 2006 B2
7052251 Nason et al. May 2006 B2
7064103 Pitner et al. Jun 2006 B2
7070580 Nielsen Jul 2006 B2
7083597 Lynch et al. Aug 2006 B2
7109878 Mann et al. Sep 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7137964 Flaherty Nov 2006 B2
7144384 Gorman et al. Dec 2006 B2
7207974 Safabash et al. Apr 2007 B2
7214207 Lynch et al. May 2007 B2
7226278 Nason et al. Jun 2007 B2
7303543 Maule et al. Dec 2007 B1
7303549 Flaherty et al. Dec 2007 B2
7310544 Brister et al. Dec 2007 B2
7318816 Bobroff et al. Jan 2008 B2
7329239 Safabash et al. Feb 2008 B2
7354420 Steil et al. Apr 2008 B2
7496392 Alarcon et al. Feb 2009 B2
7713258 Adams et al. May 2010 B2
7722595 Pettis et al. May 2010 B2
8172803 Morrissey et al. May 2012 B2
8221359 Kristensen et al. Jul 2012 B2
8262618 Scheurer Sep 2012 B2
8277415 Mounce et al. Oct 2012 B2
8285328 Caffey et al. Oct 2012 B2
8287467 List et al. Oct 2012 B2
8287516 Kornerup et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310415 McLaughlin et al. Nov 2012 B2
8313468 Geipel et al. Nov 2012 B2
20020040208 Flaherty et al. Apr 2002 A1
20030055380 Flaherty Mar 2003 A1
20030109829 Mogensen et al. Jun 2003 A1
20030176852 Lynch et al. Sep 2003 A1
20030199823 Bobroff et al. Oct 2003 A1
20040002682 Kovelman et al. Jan 2004 A1
20040010207 Flaherty et al. Jan 2004 A1
20040044306 Lynch et al. Mar 2004 A1
20040059316 Smedegaard Mar 2004 A1
20040078028 Flaherty et al. Apr 2004 A1
20040092865 Flaherty et al. May 2004 A1
20040092878 Flaherty May 2004 A1
20040116866 Gorman et al. Jun 2004 A1
20040127844 Flaherty Jul 2004 A1
20040153032 Garribotto et al. Aug 2004 A1
20040162521 Bengtsson Aug 2004 A1
20040204673 Flaherty Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040220551 Flaherty et al. Nov 2004 A1
20040235446 Flaherty et al. Nov 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050021005 Flaherty et al. Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050043687 Mogensen et al. Feb 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050090784 Nielsen et al. Apr 2005 A1
20050101912 Faust et al. May 2005 A1
20050101932 Cote et al. May 2005 A1
20050101933 Marrs et al. May 2005 A1
20050113761 Faust et al. May 2005 A1
20050124936 Mogensen et al. Jun 2005 A1
20050171512 Flaherty Aug 2005 A1
20050182366 Vogt et al. Aug 2005 A1
20050203461 Flaherty et al. Sep 2005 A1
20050215982 Malave et al. Sep 2005 A1
20050222645 Malave et al. Oct 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050273076 Beasley et al. Dec 2005 A1
20050283144 Shiono et al. Dec 2005 A1
20060001551 Kraft et al. Jan 2006 A1
20060041229 Garibotto et al. Feb 2006 A1
20060074381 Malave et al. Apr 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060129090 Moberg et al. Jun 2006 A1
20060135913 Ethelfeld Jun 2006 A1
20060142698 Ethelfeld Jun 2006 A1
20060173410 Moberg et al. Aug 2006 A1
20060178633 Garibotto et al. Aug 2006 A1
20060200073 Radmer et al. Sep 2006 A1
20060263839 Ward et al. Nov 2006 A1
20060264835 Nielsen et al. Nov 2006 A1
20060282290 Flaherty et al. Dec 2006 A1
20070016149 Hunn et al. Jan 2007 A1
20070021733 Hansen et al. Jan 2007 A1
20070049865 Radmer et al. Mar 2007 A1
20070073229 Gorman et al. Mar 2007 A1
20070073559 Stangel Mar 2007 A1
20070088244 Miller et al. Apr 2007 A1
20070088271 Richards Apr 2007 A1
20070093754 Mogensen et al. Apr 2007 A1
20070118405 Campbell et al. May 2007 A1
20070149925 Edwards et al. Jun 2007 A1
20070191702 Yodfat et al. Aug 2007 A1
20070219496 Kamen et al. Sep 2007 A1
20080004515 Jennewine Jan 2008 A1
20080021395 Yodfat et al. Jan 2008 A1
20080051697 Mounce et al. Feb 2008 A1
20080051698 Mounce et al. Feb 2008 A1
20080051709 Mounce et al. Feb 2008 A1
20080051710 Moberg et al. Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080051714 Moberg et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080051718 Kavazov et al. Feb 2008 A1
20080051727 Moberg et al. Feb 2008 A1
20080051730 Bikovsky Feb 2008 A1
20080051738 Griffin Feb 2008 A1
20080051765 Mounce Feb 2008 A1
20080097321 Mounce et al. Apr 2008 A1
20080097326 Moberg et al. Apr 2008 A1
20080097327 Bente et al. Apr 2008 A1
20080097328 Moberg et al. Apr 2008 A1
20080097375 Bikovsky Apr 2008 A1
20080097381 Moberg et al. Apr 2008 A1
20080103483 Johnson et al. May 2008 A1
20080116647 Anderson et al. May 2008 A1
20080119707 Stafford May 2008 A1
20080132842 Flaherty Jun 2008 A1
20080147041 Kristensen Jun 2008 A1
20080160492 Campbell et al. Jul 2008 A1
20080194924 Valk et al. Aug 2008 A1
20080215006 Thorkild Sep 2008 A1
20080261255 Tolosa et al. Oct 2008 A1
20080264261 Kavazov et al. Oct 2008 A1
20080269680 Ibranyan et al. Oct 2008 A1
20080269713 Kavazov Oct 2008 A1
20080281297 Pesach et al. Nov 2008 A1
20080294028 Brown Nov 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080312608 Christoffersen et al. Dec 2008 A1
20080319414 Yodfat et al. Dec 2008 A1
20090005724 Regittnig et al. Jan 2009 A1
20090005728 Weinert et al. Jan 2009 A1
20090012472 Ahm et al. Jan 2009 A1
20090062767 Van Antwerp et al. Mar 2009 A1
20090076453 Mejlhede et al. Mar 2009 A1
20090198191 Chong et al. Aug 2009 A1
20090198215 Chong et al. Aug 2009 A1
20090204077 Hasted et al. Aug 2009 A1
20090221971 Mejlhede et al. Sep 2009 A1
20090240240 Hines et al. Sep 2009 A1
20090254041 Krag et al. Oct 2009 A1
20090281497 Kamen et al. Nov 2009 A1
20090326457 O'Connor Dec 2009 A1
20100049129 Yokoi et al. Feb 2010 A1
20100160902 Aeschilimann et al. Jun 2010 A1
20100286714 Gyrn et al. Nov 2010 A1
20100291588 McDevitt et al. Nov 2010 A1
20100298830 Browne et al. Nov 2010 A1
20120253282 Nagel et al. Oct 2012 A1
20120259185 Yodfat et al. Oct 2012 A1
20120265034 Wisniewski et al. Oct 2012 A1
20120277554 Schurman et al. Nov 2012 A1
20120277667 Yodat et al. Nov 2012 A1
20120277724 Larsen et al. Nov 2012 A1
20120283540 Brüggemann Nov 2012 A1
20120291778 Nagel et al. Nov 2012 A1
20120293328 Blomquist Nov 2012 A1
20120296269 Blomquist Nov 2012 A1
20120296310 Blomquist Nov 2012 A1
20120296311 Brauker et al. Nov 2012 A1
Foreign Referenced Citations (6)
Number Date Country
0 980 687 Feb 2000 EP
WO 99-34212 Jul 1999 WO
WO 2007-051139 May 2007 WO
WO 2009010399 Jan 2009 WO
WO 2009-021039 Feb 2009 WO
WO 2009-021052 Feb 2009 WO
Related Publications (1)
Number Date Country
20120136300 A1 May 2012 US
Provisional Applications (1)
Number Date Country
61344971 Nov 2010 US